To look for a needle in a haystack: The search for autoantibodies in multiple sclerosis

Multiple Sclerosis Journal

Volumn 20, Issue 3, 2014, Pages 271-279

  Schirmer, Lucas ^a   Srivastava, Rajneesh ^a   Hemmer, Bernhard ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Technische Universität München Munich Cluster for Systems Neurology   (Germany)

Author keywords

Autoantibodies; multiple sclerosis; pathology; proteomics; review

Indexed keywords

AUTOANTIBODY; AQUAPORIN 4 ANTIBODY; CELL PROTEIN; HEAT SHOCK PROTEIN; INWARDLY RECTIFYING GLIAL POTASSIUM CHANNEL KIR4 1; INWARDLY RECTIFYING POTASSIUM CHANNEL; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUROFASCIN 155 PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PROTEOMICS; REVIEW; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ASTROCYTE; AXON; AXONAL INJURY; B LYMPHOCYTE; CEREBROSPINAL FLUID LEVEL; IMMUNE RESPONSE; MYELIN SHEATH; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANVIER NODE;

AUTOANTIBODIES; MULTIPLE SCLEROSIS; PATHOLOGY; PROTEOMICS; REVIEW;

AUTOANTIBODIES; HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; OLIGODENDROGLIA; PROTEOMICS;

EID: 84895731859     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514522104     Document Type: Review

References (72)

1. Krumbholz M, Derfuss T, Hohlfeld R, et al. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nature Rev Neurol. 2012 ; 8: 613-623
2. McLaughlin KA, Wucherpfennig KW.. B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol. 2008 ; 98: 121-149
3. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol. 2000 ; 47: 707-717 (Pubitemid 30390191)
4. Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet. 2005 ; 366: 579-582 (Pubitemid 41140333)
5. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 ; 358: 676-688 (Pubitemid 351240747)
6. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: A Phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011 ; 378: 1779-1787
7. Hemmer B, Archelos JJ, Hartung HP.. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci. 2002 ; 3: 291-301 (Pubitemid 135706608)
8. Obermeier B, Mentele R, Malotka J, et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nature Med. 2008 ; 14: 688-693 (Pubitemid 351809541)
9. Owens GP, Bennett JL, Lassmann H, et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol. 2009 ; 65: 639-649
10. Nave KA, Trapp BD.. Axon-glial signaling and the glial support of axon function. Ann Rev Neurosci. 2008 ; 31: 535-561
11. Moller JR, Johnson D, Brady RO, et al. Antibodies to myelin-associated glycoprotein (MAG) in the cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 1989 ; 22: 55-61 (Pubitemid 19064637)
12. Panitch HS, Hooper CJ, Johnson KP.. CSF antibody to myelin basic protein. Measurement in patients with multiple sclerosis and subacute sclerosing panencephalitis. Arch Neurol. 1980 ; 37: 206-209 (Pubitemid 10156361)
13. Johnson D, Hafler DA, Fallis RJ, et al. Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis. J Neuroimmunol. 1986 ; 13: 99-108 (Pubitemid 16023787)
14. Sellebjerg FT, Frederiksen JL, Olsson T.. Anti-myelin basic protein and anti-proteolipid protein antibody-secreting cells in the cerebrospinal fluid of patients with acute optic neuritis. Arch Neurol. 1994 ; 51: 1032-1036 (Pubitemid 24307286)
15. Holz A, Bielekova B, Martin R, et al. Myelin-associated oligodendrocytic basic protein: Identification of an encephalitogenic epitope and association with multiple sclerosis. J Immunol. 2000 ; 164: 1103-1109 (Pubitemid 30043740)
16. Van Haren K, Tomooka BH, Kidd BA, et al. Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis. Mult Scler. 2013 ; 19: 1726-1733
17. Quintana FJ, Farez MF, Izquierdo G, et al. Antigen microarrays identify CNS-produced autoantibodies in RRMS. Neurology. 2012 ; 78: 532-539
18. Aslam M, Kalluri SR, Cepok S, et al. The antibody response to oligodendrocyte specific protein in multiple sclerosis. J Neuroimmunol. 2010 ; 221: 81-86
19. Bronstein JM, Lallone RL, Seitz RS, et al. A humoral response to oligodendrocyte-specific protein in MS: A potential molecular mimic. Neurology. 1999 ; 53: 154-161 (Pubitemid 29329664)
20. Gold R, Linington C, Lassmann H.. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006 ; 129: 1953-1971 (Pubitemid 44289062)
21. Linington C, Bradl M, Lassmann H, et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol. 1988 ; 130: 443-454 (Pubitemid 18091372)
22. Reindl M, Linington C, Brehm U, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: A comparative study. Brain. 1999 ; 122: 2047-2056
23. Lindert RB, Haase CG, Brehm U, et al. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain. 1999 ; 122: 2089-2100
24. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003 ; 349: 139-145 (Pubitemid 36818783)
25. Kuhle J, Pohl C, Mehling M, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med. 2007 ; 356: 371-378 (Pubitemid 46148779)
26. Pelayo R, Tintore M, Montalban X, et al. Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med. 2007 ; 356: 426-428 (Pubitemid 46148809)
27. Zhou D, Srivastava R, Nessler S, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Nat Acad Sci USA. 2006 ; 103: 19057-19062 (Pubitemid 350002827)
28. Lalive PH, Menge T, Delarasse C, et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Nat Acad Sci USA. 2006 ; 103: 2280-2285 (Pubitemid 43271661)
29. O'Connor KC, McLaughlin KA, De Jager PL, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nature Med. 2007 ; 13: 211-217
30. Reindl M, Di Pauli F, Rostasy K, et al. The spectrum of MOG autoantibody-associated demyelinating diseases. Nature Rev Neurol. 2013 ; 9: 455-461
31. Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol. 2009 ; 66: 833-842
32. Probstel AK, Dornmair K, Bittner R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology. 2011 ; 77: 580-588
33. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012 ; 79: 1273-1277
34. Genain CP, Cannella B, Hauser SL, et al. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nature Med. 1999 ; 5: 170-175 (Pubitemid 29068523)
35. O'Connor KC, Appel H, Bregoli L, et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol. 2005 ; 175: 1974-1982 (Pubitemid 41023105)
36. Elliott C, Lindner M, Arthur A, et al. Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain. 2012 ; 135: 1819-1833
37. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 ; 338: 278-285 (Pubitemid 28065253)
38. Howell OW, Palser A, Polito A, et al. Disruption of neurofascin localization reveals early changes preceding demyelination and remyelination in multiple sclerosis. Brain. 2006 ; 129: 3173-3185 (Pubitemid 44871434)
39. Coman I, Aigrot MS, Seilhean D, et al. Nodal, paranodal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis. Brain. 2006 ; 129: 3186-3195 (Pubitemid 44871435)
40. Wolswijk G, Balesar R.. Changes in the expression and localization of the paranodal protein Caspr on axons in chronic multiple sclerosis. Brain. 2003 ; 126: 1638-1649 (Pubitemid 36834940)
41. Mathey EK, Derfuss T, Storch MK, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med. 2007 ; 204: 2363-2372 (Pubitemid 47529322)
42. Derfuss T, Parikh K, Velhin S, et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Nat Acad Sci USA. 2009 ; 106: 8302-8307
43. Ng JK, Malotka J, Kawakami N, et al. Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology. 2012 ; 79: 2241-2248
44. Devaux JJ, Odaka M, Yuki N.. Nodal proteins are target antigens in Guillain-Barre syndrome. J Periph Nerv Syst. 2012 ; 17: 62-71
45. Kawamura N, Yamasaki R, Yonekawa T, et al. Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology. 2013 ; 81: 714-722
46. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol. 2013 ; 73: 370-380
47. Schirmer L, Antel JP, Bruck W, et al. Axonal loss and neurofilament phosphorylation changes accompany lesion development and clinical progression in multiple sclerosis. Brain Pathol. 2011 ; 21: 428-440
48. Eikelenboom MJ, Petzold A, Lazeron RH, et al. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology. 2003 ; 60: 219-223 (Pubitemid 36152012)
49. Bartos A, Fialova L, Soukupova J, et al. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurolog Scand. 2007 ; 116: 100-107 (Pubitemid 47174178)
50. Franklin RJ, French-Constant C.. Remyelination in the CNS: From biology to therapy. Nat Rev Neurosci. 2008 ; 9: 839-855
51. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet. 2004 ; 364: 2106-2112 (Pubitemid 39626806)
52. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005 ; 202: 473-477 (Pubitemid 41186945)
53. Kalluri SR, Illes Z, Srivastava R, et al. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol. 2010 ; 67: 1201-1208
54. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4 IgG assays. Neurology. 2012 ; 78: 665-671
55. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009 ; 66: 617-629
56. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009 ; 66: 630-643
57. Tradtrantip L, Zhang H, Saadoun S, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol. 2012 ; 71: 314-322
58. Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med. 2012 ; 367: 115-123
59. Kraus V, Srivastava R, Kalluri SR, et al. Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease. Neurology. 2014 ;:
60. Lovato L, Cianti R, Gini B, et al. Transketolase and 2',3'-cyclic- nucleotide 3'-phosphodiesterase Type I isoforms are specifically recognized by IgG autoantibodies in multiple sclerosis patients. Molec Cellular Proteom. 2008 ; 7: 2337-2349
61. Rosener M, Muraro PA, Riethmuller A, et al. 2',3'-cyclic nucleotide 3'-phosphodiesterase: A novel candidate autoantigen in demyelinating diseases. J Neuroimmunol. 1997 ; 75: 28-34 (Pubitemid 27170299)
62. Archelos JJ, Trotter J, Previtali S, et al. Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis. Ann Neurol. 1998 ; 43: 15-24 (Pubitemid 28124644)
63. Cortese I, Tafi R, Grimaldi LM, et al. Identification of peptides specific for cerebrospinal fluid antibodies in multiple sclerosis by using phage libraries. Proc Nat Acad Sci USA. 1996 ; 93: 11063-11067 (Pubitemid 26333118)
64. Somers V, Govarts C, Somers K, et al. Autoantibody profiling in multiple sclerosis reveals novel antigenic candidates. J Immunol. 2008 ; 180: 3957-3963
65. Govarts C, Somers K, Hupperts R, et al. Analysis of antibody reactivity in paired cerebrospinal fluid and serum of a relapsing-remitting multiple sclerosis patient. Autoimmunity. 2009 ; 42: 699-704
66. Rouwette M, Noben JP, Van Horssen J, et al. Identification of coronin-1a as a novel antibody target for clinically-isolated syndrome and multiple sclerosis. J Neurochem. 2013 ; 126: 483-492
67. Cepok S, Zhou D, Srivastava R, et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest. 2005 ; 115: 1352-1360 (Pubitemid 40629055)
68. Quintana FJ, Farez MF, Viglietta V, et al. Antigen microaridentify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America. 2008 ; 105 (48). 18889-18894
69. Querol L, Clark PL, Bailey MA, et al. Protein array-based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis. Neurology. 2013 ; 81: 956-963
70. Mange A, Lacombe J, Bascoul-Mollevi C, et al. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer. Clin Can Res. 2012 ; 18: 1992-2000
71. Kanter JL, Narayana S, Ho PP, et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nature Med. 2006 ; 12: 138-143 (Pubitemid 43050089)
72. Ousman SS, Tomooka BH, Van Noort JM, et al. Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature. 2007 ; 448: 474-479 (Pubitemid 47123511)